These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32040618)

  • 1. Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma.
    Asahi Y; Hatanaka KC; Hatanaka Y; Kamiyama T; Orimo T; Shimada S; Nagatsu A; Sakamoto Y; Kamachi H; Kobayashi N; Fukai M; Taketomi A
    Surg Today; 2020 Aug; 50(8):931-940. PubMed ID: 32040618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
    Sabbatino F; Villani V; Yearley JH; Deshpande V; Cai L; Konstantinidis IT; Moon C; Nota S; Wang Y; Al-Sukaini A; Zhu AX; Goyal L; Ting DT; Bardeesy N; Hong TS; Fernandez-del Castillo C; Tanabe KK; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2016 Jan; 22(2):470-8. PubMed ID: 26373575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
    Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
    Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8
    Miyazaki K; Morine Y; Imura S; Ikemoto T; Saito Y; Yamada S; Tokuda K; Okikawa S; Yamashita S; Oya T; Tsuneyama K; Shimada M
    Surg Today; 2021 Dec; 51(12):1985-1995. PubMed ID: 34009433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma.
    Lin G; Liu Y; Li S; Mao Y; Wang J; Shuang Z; Chen J; Li S
    Oncotarget; 2016 Aug; 7(32):50963-50971. PubMed ID: 26918355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
    Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
    J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
    Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
    World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of resectable intrahepatic cholangiocarcinoma.
    Chou FF; Sheen-Chen SM; Chen CL; Chen YS; Chen MC
    J Surg Oncol; 1995 May; 59(1):40-4. PubMed ID: 7745976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
    Nakamura M; Ueno M; Hayami S; Kawai M; Miyamoto A; Suzaki N; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Kojima F; Yamaue H
    Anticancer Res; 2020 Jul; 40(7):4123-4129. PubMed ID: 32620661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Mod Pathol; 2021 Apr; 34(4):798-807. PubMed ID: 33077921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status.
    Yugawa K; Itoh S; Iseda N; Kurihara T; Kitamura Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Yoshizumi T; Mori M
    Sci Rep; 2021 Mar; 11(1):5845. PubMed ID: 33712681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.
    Kitano Y; Okabe H; Yamashita YI; Nakagawa S; Saito Y; Umezaki N; Tsukamoto M; Yamao T; Yamamura K; Arima K; Kaida T; Miyata T; Mima K; Imai K; Hashimoto D; Komohara Y; Chikamoto A; Ishiko T; Baba H
    Br J Cancer; 2018 Jan; 118(2):171-180. PubMed ID: 29123259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
    Fontugne J; Augustin J; Pujals A; Compagnon P; Rousseau B; Luciani A; Tournigand C; Cherqui D; Azoulay D; Pawlotsky JM; Calderaro J
    Oncotarget; 2017 Apr; 8(15):24644-24651. PubMed ID: 28445951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of CD163+ Macrophages in Tumor Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct Cancer.
    Miura T; Yoshizawa T; Hirai H; Seino H; Morohashi S; Wu Y; Wakiya T; Kimura N; Kudo D; Ishido K; Toyoki Y; Kijima H; Hakamada K
    Anticancer Res; 2017 Jan; 37(1):183-190. PubMed ID: 28011489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
    Sato Y; Kinoshita M; Takemura S; Tanaka S; Hamano G; Nakamori S; Fujikawa M; Sugawara Y; Yamamoto T; Arimoto A; Yamamura M; Sasaki M; Harada K; Nakanuma Y; Kubo S
    Pathol Int; 2017 Mar; 67(3):163-170. PubMed ID: 28139862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma.
    Matsumura N; Yamamoto M; Aruga A; Takasaki K; Nakano M
    Cancer; 2002 Mar; 94(6):1770-6. PubMed ID: 11920540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.
    Carapeto F; Bozorgui B; Shroff RT; Chagani S; Solis Soto L; Foo WC; Wistuba I; Meric-Bernstam F; Shalaby A; Javle M; Korkut A; Kwong LN
    Hepatology; 2022 Feb; 75(2):297-308. PubMed ID: 34510503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion.
    Ye Y; Zhou L; Xie X; Jiang G; Xie H; Zheng S
    J Surg Oncol; 2009 Nov; 100(6):500-4. PubMed ID: 19697355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location.
    Kunk PR; Dougherty SC; Lynch K; Whitehair R; Meneveau M; Obeid JM; Winters K; Ju JY; Stelow EB; Bauer TW; Slingluff CL; Rahma OE
    J Immunother; 2021 Sep; 44(7):254-263. PubMed ID: 34191790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.